Nuvation Bio Inc. (NUVB)

Every figure this model derived for NUVB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 660,956,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 726,432,000 AssetsCurrent 2026-06-30
current liabilities 86,755,000 LiabilitiesCurrent 2026-06-30
equity 253,864,000 StockholdersEquity 2026-06-30
interest expense 26,674,000 InterestExpenseNonoperating 2026-06-30
ocf -120,522,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 169,900,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 35,502,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NUVB on one particular measure came for.

RatioValue
cash operating margin-58.85
current ratio9.33
current ratio reported8.37
deferred revenue growth-8.95
dilution pct27.1
fcf margin-70.94
interest cover-5.16
operating margin-81.0
owner earnings margin-91.83
revenue growth1083.56
revenue growth per share831.24
rule of 401002.56
sbc pct revenue20.9

What to be careful about

What this model itself distrusts about NUVB's figures. Written by the derivation as it ran, not added afterwards.